2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Profiling, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, AML, MDS, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

6044 Interferonαmaintenance after Allogeneic hematopoietic Cell Transplantation for TP53-mutant acute Myeloid Leukemia and Myelodysplastic Syndromes:a single-arm, phase 2 trial

Yu Wang, Xiaosu Zhao2, Ying-Jun Chang3, Yuanyuan Zhang4, Yuqian Sun, MD5, Xiao-Dong Mo, MD6, Yi-Fei Cheng, MD7, Lanping Xu, MD8, XiaoHui Zhang9, Xiaojun Huang, MD, PhD10
1 Peking University People's Hospital, Beijing, China
2 Peking University People's Hospital, Beijing, China
3 Peking University People's Hospital, Beijing, China
4 Peking University People's Hospital, Beijing, China
5 Peking University People's Hospital, Beijing, China
6 Peking University People's Hospital, Beijing, China
7 Peking University People's Hospital, Beijing, China
8 Peking University People's Hospital, Beijing, China
9 Peking University People's Hospital, Beijing, China
10 Peking University People's Hospital, Beijing, China

PURPOSE Outcomes are poor in TP53-mutant (mTP53) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), even after allogeneic hematopoietic stem-cell transplant (HCT). Interferonα (IFN-α) therapy, which can strengthen the GVL effect, has been reported as an efficient therapy in patients with AML or MDS..

PATIENTS AND METHODS We conducted a phase II, open-label trial to assess efficacy and safety of IFN-αas maintenance therapy after HCT (ClinicalTrials.gov identi?er: NCT06130579). IFN-α3 million units twice per week was scheduled subcutaneously on days 75 post HCT. Maintenance treatment was continued for a maximum of 12 months. The primary outcomes were relapse incidence and safety.

RESULTS Of the 95 patients screened for eligibility before HCT, 66 received a transplant. Forty-one patients ultimately received maintenance treatment (16 AML and 25 MDS); the median age was 52 (range, 17-66) years. The median duration of IFN-αadministration was 203 days (range, 13-650), and 16 patients (39%) completed 12 planned months of therapy. With a median follow-up of 18.9 months, The 1-year CIR rate was 18.2% (95% CI, 6.4 to 30.0); the median RFS was not reached; the 1-year RFS and 2-year probability was 77.9% (95% CI, 64.9 to 90.9) and 72.3% (95% CI, 56.1 to 88.5), respectively. The median overall survival (OS) was not reached; the 1-year and 2-year OS probability was 82.6% (95% CI, 70.6 to 94.6) and 79.6% (95% CI, 66.6 to 92.6), respectively. Thirty-day and 60- day mortality from the first dose were 0% . Acute and chronic (moderate to severe) graft- versus-host disease adverse events were reported in 2.4% (n = 1) and 24% (n = 10) of patients, respectively.

CONCLUSION In patients with mTP53 AML and MDS, post-HCT maintenance therapy with Interferonαwas well tolerated. RFS and OS outcomes were encouraging in this high-risk population.

Yu Wang: No relevant conflicts of interest to declare.